Balstilimab is nearing submission to FDA for commercial approval.
Agenus has a remarkably broad pipeline that is coming to fruition.
Several events in the next 12 months could propel the stock higher.
Agenus (AGEN) is a commercial stage pharmaceutical company because of its royalties from QS-21, which is a component of Shingrix. It acts more like a clinical-stage company, however, because it pre-spent the Shingrix